Preparation and evaluation of tilmicosin-loaded hydrogenated castor oil nanoparticle suspensions of different particle sizes

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 2655-2664

  Chen, Xiaojin ^a   Wang, Ting ^a   Lu, Mengmeng ^a   Zhu, Luyan ^a   Wang, Yan ^a   Zhou, Wen Zhong ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

Antibacterial activity; Particle size; Release rate; Solid lipid nanoparticle suspension; Tilmicosin; Toxicity

Indexed keywords

HYDROGENATED CASTOR OIL; NANOPARTICLE; POLYVINYL ALCOHOL; SURFACTANT; TILMICOSIN; TILMICOSIN LOADED HYDROGENATED CASTOR OIL NANOPARTICLE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CASTOR OIL; NANOCAPSULE; SUSPENSION; TYLOSIN;

ACUTE TOXICITY; ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; ECHOGRAPHY; FEMALE; HOT HOMOGENIZATION; IN VITRO STUDY; MALE; METHODOLOGY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; POWDER; PROCESS OPTIMIZATION; ROOM TEMPERATURE; ANALOGS AND DERIVATIVES; ANIMAL; BACTERIAL PHENOMENA AND FUNCTIONS; CELL SURVIVAL; CHEMISTRY; DIFFUSION; DOSE RESPONSE; DRUG EFFECTS; HYDROGENATION; SURVIVAL RATE; SUSPENSION; TOXICITY; ULTRASTRUCTURE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PHYSIOLOGICAL PHENOMENA; CASTOR OIL; CELL SURVIVAL; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDROGENATION; MALE; MICE; NANOCAPSULES; PARTICLE SIZE; SURVIVAL RATE; SUSPENSIONS; TYLOSIN;

EID: 84901494473     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S58898     Document Type: Article

References (42)

1. Ose EE. In vitro antibacterial properties of EL-870, a new semi-synthetic macrolide antibiotic. J Antibiot (Tokyo). 1987;40(2):190-194.
2. Ziv G, Shem-Tov M, Glickman A, Winkler M, Saran A. Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther. 1995;18(5):340-345.
3. Ramadan A. Pharmacokinetics of tilmicosin in serum and milk of goats. Res Vet Sci. 1997;62(1):48-50.
4. Backstrom L, McDonald J, Collins MT, Chung WB, Shyrock TR, Ose EE. Efficacy of tilmicosin, and a combination of tylosin and sulfamethazine, for control of swine atrophic rhinitis involving infection with toxigenic Pasturella multocida type D. Swine Health and Production. 1994;2(4):11-14.
5. FAO. Residue of some veterinary drugs in animals and foods: Tilmicosin, FAO/WHO Expert Committee on Food Additives. 1996.
6. Xu Z, Wang J, Shen W, Cen P. Study on the extraction equilibrium of tilmicosin between the aqueous and butyl acetate phases. Chem Eng Commun. 2006;193(4):427-437.
7. Wang XF, Zhang SL, Zhu LY, etal. Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivo. Vet J. 2012;191(1):115-120.
8. Han C, Qi CM, Zhao BK, etal. Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J Vet Pharmacol Ther. 2009;32(2):116-123.
9. Xie S, Wang F, Wang Y, etal. Acute toxicity of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles. Part Fibre Toxicol. 2011;8:33.
10. Freitas C, Müllerä RH. Spray-drying of solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm. 1998;46(2):145-151.
11. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-1272.
12. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
13. Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev. 2007;59(6):444-453.
14. Morley PS, Apley MD, Besser TE, etal; American College of Veterinary Internal Medicine. Antimicrobial drug use in veterinary medicine. J Vet Intern Med. 2005;19(4):617-629.
15. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3): 165-196.
16. Matschke C, Isele U, van Hoogevest P, Fahr A. Sustained-release injectables formed in situ and their potential use for veterinary products. J Control Release. 2002;85(1-3):1-15.
17. Tallury P, Payton K, Santra S. Silica-based multimodal/multifunctional nanoparticles for bioimaging and biosensing applications. Nanomedicine (Lond). 2008;3(4):579-592.
18. Smith AM, Duan H, Mohs AM, Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev. 2008;60(11):1226-1240.
19. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420(1):1-10.
20. Müller RH, Keck CM. Twenty years of drug nanocrystals: where are we, and where do we go? Eur J Pharm Biopharm. 2012;80(1): 1-3.
21. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011;78(1):1-9.
22. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63(6):427-440.
23. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008; 36(1):43-48.
24. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19(12):930-934.
25. Tomazic-Jezic VJ, Merritt K, Umbreit TH. Significance of the type and the size of biomaterial particles on phagocytosis and tissue distribution. J Biomed Mater Res. 2001;55(4):523-529.
26. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically; Approved Standards-Seventh Edition. Clinical and Laboratory Standards Institute document M7-A7 [ISBN 1-56238-587-9]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006.
27. Well M, Naber KG, Kinzig-Schippers M, Sörgel F. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. Int J Antimicrob Agents. 1998;10(1):31-38.
28. Zambaux MF, Bonneaux F, Gref R, etal. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release. 1998;50(1-3):31-40.
29. Lee SC, Oh JT, Jang MH, Chung SI. Quantitative analysis of polyvinyl alcohol on the surface of poly(D, L-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration. J Control Release. 1999;59(2):123-132.
30. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002;82(1):105-114.
31. Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release. 2001;70(3):353-363.
32. Misra R, Acharya S, Dilnawaz F, Sahoo SK. Sustained antibacterial activity of doxycycline-loaded poly(D, L-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles. Nanomedicine (Lond). 2009;4(5):519-530.
33. Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco MR. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm. 2000;210(1-2):61-67.
34. Serpe L, Catalano MG, Cavalli R, etal. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm. 2004;58(3):673-680.
35. Zbinden G, Flury-Roversi M. Significance of the LD50-test for the toxicological evaluation of chemical substances. Arch Toxicol. 1981;47(2):77-99.
36. Watson WC, Gordon RS. Studies on the digestion, absorption and metabolism of castor oil. Biochem Pharmacol. 1962;11:229-236.
37. DeMerlis CC, Schoneker DR. Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem Toxicol. 2003;41(3):319-326.
38. Ghaffari S, Varshosaz J, Saadat A, Atyabi F. Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles. Int J Nanomedicine. 2011;6:35-43.
39. Xie S, Pan B, Shi B, etal. Solid lipid nanoparticle suspension enhanced the therapeutic efficacy of praziquantel against tapeworm. Int J Nanomedicine. 2011;6:2367-2374.
40. Paliwal R, Rai S, Vaidya B, etal. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine. 2009;5(2):184-191.
41. Shegokar R, Singh KK, Müller RH. Production and stability of stavudine solid lipid nanoparticles-from lab to industrial scale. Int J Pharm. 2011;416(2):461-470.
42. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95(3):627-638.